Eton Pharmaceuticals ( (ETON) ) has released its Q1 earnings. Here is a breakdown of the information Eton Pharmaceuticals presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, with a portfolio of seven commercial products and six additional candidates in late-stage development.
In the first quarter of 2025, Eton Pharmaceuticals reported significant financial growth, with revenues reaching $17.3 million, marking a 117% increase from the previous year. The company also relaunched two key products, INCRELEX® and GALZIN®, and made strategic advancements in its development pipeline.
Key financial highlights include a 76% growth in product sales, driven by ALKINDI SPRINKLE® and the addition of INCRELEX®. The company reported a non-GAAP net income of $2.4 million and an adjusted EBITDA of $3.7 million. Eton also announced the submission of a New Drug Application for ET-600 and the anticipated launch of ET-400.
Eton’s strategic initiatives included out-licensing INCRELEX® rights outside the U.S. and expanding its Wilson disease franchise with the acquisition of GALZIN® and the introduction of ET-700. The company expects continued growth in product sales and aims to exit 2025 with an $80 million annual revenue run rate.
Looking forward, Eton Pharmaceuticals is poised for a promising year with multiple product launches and ongoing development of late-stage candidates, reinforcing its position as a leader in the ultra-rare disease sector.